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Abstract
Background: Increased consumption of foods containing plant sterols has the potential to reduce the
incidence of coronary heart disease (CHD) and thus reduce costs associated with treating that disease in a
significant way. This paper reports the results of an investigation of the potential monetary benefits of
allowing foods enriched with plant sterols to be marketed in Canada.
Objective: The objective of this research was to estimate the annual savings that would accrue to Canada’s
single-payer publicly funded health care system if plant sterols were approved for use. If foods containing
plant sterols are consumed at a sufficient rate, a reduction in CHD should follow. Given the significant costs
associated with CHD, approval of plant sterols in Canada has important public policy implications.
Design: This research employs a variation of traditional cost-of-illness analysis entailing four steps:
(1) estimation of a ‘success rate’ (proportion of persons who would consume plant sterols at the necessary
rate); (2) presumption of blood cholesterol reduction due to plant sterol consumption; (3) assumption of
reduction in CHD that follows from blood cholesterol reduction; and (4) calculation of cost savings
associated with reduced incidence of CHD.
Results: Calculations were carried out for four scenarios: ideal, optimistic, pessimistic, and very pessimistic.
It was estimated that between $38 million (very pessimistic scenario) and $2.45 billion (ideal scenario) could
be saved annually by Canada’s health care system with plant sterol-enriched food products being made
available for sale.
Conclusion: Significant expenditure reductions within Canada’s publicly funded health care system could be
realized with plant sterols approved for sale. Reduced CHD resulting from lower blood cholesterol levels
would lessen the financial burden of disease in Canada.
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T
he potential health benefits gained from consum-
ing plant sterol-enriched foods have been studied
as early as the 1950s (1), with the preponderance
of literature indicating that plant sterol and stanol-
enriched food can reduce blood cholesterol in humans
(25). In 2006, new harmonized regulations were adopted
by the European Union (EU) regarding use of health
claims and nutrition claims for food products; the new
legislation requires clear scientific substantiation of all
such claims. Recently, the European Food Safety Author-
ity approved the claim that ‘Plant sterols have been shown
to lower/reduce blood cholesterol. Blood cholesterol low-
ering may reduce the risk of (coronary) heart disease’ (6).
High blood cholesterol is a major risk factor for heart
disease and stroke; individualswith high blood cholesterol
have a greater likelihood of developing coronary heart
disease (CHD). Thus, if consumption of foods containing
plant sterols can reduce the number of individuals with
high cholesterol, it follows that consumption of plant
sterols should lead to a corresponding decrease in the
incidence of CHD. Statistics Canada in 1998 estimated
outlays for physician services, hospital costs, lost wages,
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CHD in Canada to be approximately $18 billion (7).
Accordingly, it is expected that a lowering of the incidence
of heart disease will result in a reduction of some of the
costs associated with treating CHD.
In Canada, as in other jurisdictions with publicly
funded health care systems, the rising costs of treating
diseases and the economic production lost due to
premature death and disability are a major concern.
The potential economic impact of incorporating plant
sterols into Canadians’ diets can be calculated by
determining the proportion of the estimated $18 billion
cost of CHD avoidable by allowing public consumption
of plant sterols in Canada. Previous research has shown
that consumption of plant sterol-enriched margarine
could result in significant benefits from the perspective
of a European health insurer (8); however, no comparable
research has been done in a Canadian context to date. A
previous attempt to estimate the potential economic
impact in Canada from the introduction of trans-fat-
free canola oil showed a significant reduction in the costs
associated with CHD (9). A similar approach could be
taken with respect to plant sterol-enriched food.
The purpose of this research is therefore to determine
the potential economic savings associated with allowing
plant sterol consumption in Canada. The process to
establish the potential value of these economic savings
from the consumption of plant sterol-containing foods
involves four steps: (1) assessment of a ‘success’ rate;
(2) presumption of a possible blood cholesterol reduction
due to consumption of foods containing plant sterols;
(3) assumption of the reduction in the incidence of CHD
due to the realized decrease in blood cholesterol levels;
and (4) calculation of the reduction in costs associated
with decreased prevalence of CHD. Results provide an
early approximation of the potential health care savings
associated with use of plant sterol-enriched foods; it is
expected that future research using more elaborate
techniques will yield more refined estimates.
Methods
When attempting to measure potential health benefits,
a number of methods are available including costbenefit
analysis, cost-effectiveness analysis, and cost-of-illness
analysis. The selection of an appropriate method should
be consistent with the available data and the phenomenon
being studied. Costbenefit analysis and cost-effectiveness
analysis are both used for evaluation of two or more
alternative treatments; these techniques require the costs
associated with both the treatment and the alternatives
to be well-known. The purpose of this research is to
determine the potential benefits from allowing plant
sterol-enriched foods to be sold into a market where they
are currently not available, not to compare plant sterol-
enriched foods to alternative treatments. Additionally, it is
not possible to estimate the cost premium that would be
attached to foods enrichedwith plant sterols in Canada as
this market would need to evolve in order to establish a
long-term price. As such, neither cost-effectiveness nor
costbenefit analysis is an appropriate tool for this
analysis.
A cost-of-illness analysis measures the direct and
indirect costs of a specific disease  in this case CHD.
A variation of a cost-of-illness analysis is to calculate the
dollar savings associated with preventing or avoiding
an illness. This variation has been used to calculate
the economic benefit of drug abuse interventions (10),
preventable drug-related medical complications (11), and
trans-fat-free canola oil (9). A similar approach to the
technique employed here was used previously by Malla,
Hobbs, and Perger to estimate health care savings from
trans-fat-free canola oil in Canada (12).
The economic benefit of consumption of plant sterol-
containing foods is evaluated using an economic simula-
tion involving four steps, described below.
Step 1: assessment of a ‘success rate’
In order to realize health benefits from plant sterols, an
individual must consume between 1 and 3 g/day. The
proportion of the Canadian population that will consume
a sufficient quantity of plant sterol-enriched foods to
reduce their cholesterol level is defined as the success rate.
Plant sterols can feasibly be added to a number of food
products such as orange juice, cheese, milk, yogurt, salad
dressing, cereal products, cooking oils, and margarine.
According to Statistics Canada, the average Canadian
consumption of these food categories is around nine
servings per day (13). It is thus reasonable to conclude
that there is sufficient scope within the Canadian diet to
accommodate an adequate dose of plant sterols without
having to drastically alter food consumption patterns.
It should be noted that all of the foods listed above may
not be equally effective as delivery vehicles for plant
sterols; it may also be the case that claims will be allowed
for different foods containing plant sterols along different
timelines.
Since the market for plant sterol-enriched foods has
not until very recently existed in Canada, estimating its
size and characteristics is difficult. The overall Canadian
functional food market, of which phytosterol fortified
foods will become a subset, is still evolving and changing
rapidly and thus available data are relatively sparse.
Given the lack of available information, the best method
for predicting how Canadians would respond to plant
sterol-enriched food products is to examine the markets
for similar functional foods in Canada and plant sterol-
enriched foods in other countries.
An activities, interests, and opinions (AIO) framework
and cluster analysis was used to determine the potential
markets for functional foods in Canada (14). Survey
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analysis to determine attitudes, knowledge, and motiva-
tions combining to identify consumers likely to buy
functional foods. It was discovered that a cluster
representing approximately 47% of the adult Canadian
population possesses the characteristics that would make
them likely to purchase functional food products.
Canadian survey data available to determine the accep-
tance of specific functional foods are limited when
compared to larger markets; however, the acceptance of
conjugated linoleic acid (CLA) fortified foods has been
examined in Western Canada (15). It was found that the
high percentage of survey respondents likely to purchase
CLA-enriched dairy products, if available where they
normally shop, ranged from 4% to 13%. Since many of
these dairy products are similar to potential phytosterol-
fortified foods, it seems reasonable to extend these results
to such products.
In Finland, a country which has allowed phytosterol/
stanol-fortified foods in the marketplace for quite some
time, a survey found 17% of adults reported daily use
of plant sterol-enriched margarine, with another 20%
reporting monthly use (16). An additional 7% indicated
having occasionally used the product. For the purpose of
this economic evaluation, the success rates shown
in Table 1 were used in the various sensitivity analysis
scenarios as an estimate of the success ratio.
Step 2: presumption of a possible blood cholesterol
reduction due to consumption of foods containing plant
sterols
The primary health benefit of consuming foods fortified
with phytosterols is a reduction in serum cholesterol
levels. Approximating this reduction requires extrapola-
tion of results of meta-analyses of available human
phytosterol-feeding studies. Since plant sterols are
relatively well-established as functional food additives,
several thorough meta-analyses exist (25). One of these
was limited in scope to plant sterol-enriched spreads and
found a reduction in LDL-cholesterol of 8.4% (95%
CI 6.610.0%) (3). Another included 23 plant sterol and
stanol trials and found a serum cholesterol reduction
ranging between 4.6 and 24.3% with a mean LDL-
cholesterol reduction of 11.0% (4). Yet another used 21
published plant sterol studies found that average dose of
2.3 g of plant sterols per day yielded an average
cholesterol reduction of 9.7% (95% CI 8.510.8%) (2).
The most recent meta-analysis examined the results of 59
studies and found that plant sterol containing products
reduced LDL-cholesterol by 0.31 mmol/L, a significant
reduction (5).
The results from the meta-analysis based on 21
published plant sterol studies (2) were adopted for the
majority of the scenarios in the sensitivity analysis. This
work included the largest number of trials limited
exclusively to plant sterol-enriched foods and did not
include plant stanol-enriched foods. As a result, this
dataset was judged as best representing the relationship
between plant sterol consumption and serum LDL-
cholesterol level reduction in humans.
Step 3: assumption of the reduction in the incidence of CHD
due to decrease in blood cholesterol levels
Since no long-term studies have directly tracked the
relationship between phytosterol consumption and heart
disease in humans, it was necessary to make assumptions
regarding the rate at which lower cholesterol levels due to
plant sterol consumption will reduce the incidence of
CHD. A meta-analysis of cholesterol-reducing treatment
studies found a 1314% reduction in CHD mortality for
every 10-percentage-point net reduction in serum choles-
terol levels (17). In a similar examination of studies
concerning the relationship between cholesterol levels
and ischemic heart disease, it was found that a 10%
cholesterol reduction would lead to a 2530% reduction
in mortality from ischemic heart disease over the long-
term (18). As both those studies focused on reductions in
CHD mortality, it seems likely that the non-fatal
incidence of CHD would decrease in a similar fashion
if serum cholesterol was reduced across the population.
In an economic evaluation of the health benefits
associated with trans-fat-free canola oil, a ratio of a 1%
reduction of cholesterol corresponding to 23% reduction
in the incidence of CHD was utilized (9). This result is
consistent with the findings of previous research (17, 18)
and was therefore used as the assumption regarding the
reduction in the incidence of CHD due to decreased
blood cholesterol levels resulting from plant sterol con-
sumption in the majority of the sensitivity analysis
scenarios.
Step 4: calculation of the reduction in costs associated with
CHD due to a reduction in the overall incidence of CHD
The final step in the procedure is to quantify the
economic benefit resulting from introducing plant
sterol-enriched food to the Canadian market. Health
Canada has estimated the cost of CHD in Canada
Table 1. Estimated plant sterol success rates
Assumption
Plant sterol
consumption rate (%) Source
Full potential all consumers
who are predisposed to
purchase functional food
47 Herath et al. (14)
Consumption level similar
to Europe
17 Niva (16)
Consumption level similar
to CLA survey intentions
10 Peng et al. (15)
Healthcare savings from plant sterol use in Canada
Citation: Food & Nutrition Research 2010, 54: 5113 - DOI: 10.3402/fnr.v54i0.5113 3
(page number not for citation purpose)(7); even though the data are more than a decade old,
they are still the most recent and comprehensive available.
Since the 1998 data are in nominal dollar amounts but
health care costs are subject to inflation, the 1998
amounts require adjustment to more current monetary
terms. This adjustment is made using Statistics Canada’s
consumer price index for health and personal care (19).
Adjustment of the 1998 estimate of $18.472 billion to
2007 levels yields a new approximation of $21.176 billion
as the assumed economic cost of CHD in Canada.
The economic cost of disease is generally broken down
into direct and indirect components; the former are
incurred directly by the health care system with the
goal of improving and/or preventing a patient’s health
status from deteriorating. In the case of heart disease,
direct costs include hospital care, drug costs, physician
expenses, and other miscellaneous items. Indirect costs
are those incurred due to the loss of production arising
from disease and include loss of production due to
mortality and morbidity costs arising from long- and
short-term disability. Table 2 provides a summary of
direct and indirect costs attributable to CHD in Canada
in both 1998 and inflation-adjusted 2007 dollars. While
it seems obvious that a reduction in the level of CHD will
lower related costs, is the extent to which these costs will
be lowered is less clear. Previous work utilized a directly
proportional relationship and assumed that a 1% reduc-
tion in CHD would result in a 1% reduction in
CHD-related costs (9). This type of assumption may
oversimplify the health care process and could thus result
in an overstatement of the potential cost reduction.
Rather than assuming a proportional cost reduction, it
is appropriate to more closely examine the nature of
specific cost categories. For example, hospitalization
expenditures related to CHD include a sizeable fixed
cost component  the costs of operating a hospital will be
incurred regardless of the number of heart attack patients
treated at the hospital. Research conducted with respect
to the fixed cost variable cost breakdown in hospitals
found that hospital costs are approximately 84% fixed
and 16% variable (20). Accordingly, it is assumed that a
reduction in CHD will not result in a reduction in fixed
costs of hospitalization, but will cause a proportional
reduction in variable hospitalization costs.
Approximating the reduction in drug costs due to
CHD assumes that fewer individuals with CHD will
require less medication to treat CHD. Since 49.6% of
drug costs resulting from CHD are for the treatment
of hypertension (7), a condition not normally improved
as a result of cholesterol reduction, these costs are not
reduced in the calculations. The remaining 50.4% of drug
costs associated with CHD are reduced proportionally to
the reduction in the overall rate of CHD. Physician care
costs associated with CHD are based on physician
billings which in turn are derived from patient visits to
doctors’ offices. It is assumed that if fewer people are
afflicted with CHD, fewer visits to physicians for CHD
treatment will occur, resulting in less numerous billings
and lower health care costs. As such, a 1% reduction in
CHD is assumed to lead to a 1% reduction in CHD-
related physician costs.
A large component of the miscellaneous CHD-related
expenditures has been categorized by Health Canada (7)
as services provided by ‘other health providers.’ For this
analysis, the cost of chiropractors (0.8%), dental (26.2%),
and vision (9.6%) health professionals were excluded, as
such costs are unlikely to be reduced due to a reduction in
heart disease. However, the cost of physiotherapists (1%)
and ‘all other health professionals’ (4.7%) should be
reduced in proportion to the overall CHD reduction.
Also ignored in this analysis are costs which are largely
fixed and therefore unlikely to decrease with the rate of
CHD: expenditures on health research (4.4%), adminis-
tration (6.5%), and public health (20.2%). By contrast,
costs that will likely be reduced by a reduction in CHD
include ambulance (4.2%), home care (6.2%), and ‘all
other health expenditures’ (7.2%). The final result is that a
1% decrease in the incidence of CHD is expected to result
in a 0.23% reduction in miscellaneous CHD-related costs.
Mortality, short-term disability, and long-term disabil-
ity costs were taken to have a directly proportional CHD
reduction to reduction in cost relationship. Since the
incidence of CHD will decline, it was deemed reasonable
to assume the number of people who will die or become
disabled as a result of CHD will decline proportionately.
As a consequence, the loss of human capital that would
ordinarily be incurred as a result of CHD-related death
and disability, would not take place; this reduction results
in an economic saving. Table 3 summarizes the proportion
Table 2. Summary of costs attributed to coronary heart disease in
Canada ($ millions)
Cost category 1998 2007
Direct costs
Hospital 4161.8 4771.0
Drugs 1772.8 2032.3
Physician care 822.3 942.7
Other Direct 61.2 70.2
Total direct costs 6818.1 7816.0
Indirect costs
Mortality 8250.0 9457.5
Long-term disability 3151.5 3612.8
Short-term Disability 253.3 290.4
Total indirect costs 11654.8 13360.7
Total CHD costs 18472.9 21176.7
Source: Health Canada (7).
Collin L. Gyles et al.
4
(page number not for citation purpose)
Citation: Food & Nutrition Research 2010, 54: 5113 - DOI: 10.3402/fnr.v54i0.5113of cost reductions that could be achieved by a reduction in
the incidence of CHD.
A number of assumptions are required to approximate
the potential reduction in the cost of CHD from
introducing phytosterol-fortified foods to the Canadian
market. Though these assumptions are based on a review
of the peer-reviewed scientific literature, it could be
misleading to suggest a single number as best represent-
ing the exact economic cost savings. As such, results are
reported as a sensitivity analysis; this approach allows
the effects of varying model assumptions within the
simulation to be gauged. To make the numbers
as robust as possible, four scenarios were examined;
a description of the sensitivity analysis scenarios is
provided below with a summary of the assumptions
shown in Table 4.
Results and discussion
The ‘ideal’ scenario is one in which the most positive
assumptions are used to calculate the greatest possible
economic benefit of allowing consumption of plant
sterol-enriched food in Canada. It is unlikely that this
scenario is achievable in the short-term; however, over the
long-term this estimate provides an index of the full
potential of the economic savings resulting from the
consumption of plant sterol-enriched foods in Canada.
The ‘optimistic’ and ‘pessimistic’ scenarios make more
reasonable assumptions and represent a medium-to-
short-term estimate of the potential economic savings
possible through plant sterol consumption. The ‘very
pessimistic’ scenario is included to determine the impact
on the cost estimations under a worst-case scenario.
This scenario could be considered appropriate if the
acceptance of phytosterol fortified foods is very low and
the efficacy of plant sterols in reducing cholesterol and
the health benefits of cholesterol reduction are consider-
ably below expectations.
Table 5 shows the range of values calculated to be
representative of the economic savings to Canada from
allowing plant sterols in the diet of Canadians. Each of
the direct and indirect cost components is represented for
the ideal, optimistic, pessimistic, and very pessimistic
scenarios described above. Under even the most pessi-
mistic set of assumptions, substantial cost savings would
be realized to Canada’s publicly funded single-payer
health system. Under more reasonable assumptions,
the savings become increasingly significant. Although it
is unlikely the ideal scenario would be achieved in the
short term, it is evident that under avery optimistic set of
assumptions, the potential savings become substantial.
The dynamic process from the point in time when plant
sterol-enriched foods are introduced to the market to the
point in time at which the savings predicted in the various
scenarios will occur is difficult to model with certainty.
The scenarios presented in this paper represent a static
picture at some point in the future. How quickly the
product is adopted will determine the speed with which
that point is reached. The ideal scenario with a high
success rate is more likely to occur at apoint in time that is
further into the future than the optimistic or pessimistic
scenarios which have lower success rates built into their
models. While a specific timeline cannot be predictedwith
certainty, the optimistic scenario requires that Canadians
adopt phytosterol-fortified foods in a manner similar to
that of Finland, which does not seem unreasonable. Based
on the introduction pattern of plant sterol-enriched foods
in Finland over the 1990s of 17%, it would be reasonable
to conclude that the impact of introducing plant sterol
fortified foods into the Canadian market could be realized
in a period of 510 years.
General discussion and conclusions
The results of the simulation indicate that substantial
economic savings can result from introducing plant
Table 3. Summary of coronary heart disease cost reduction corre-
sponding to a 1% decrease in incidence of coronary heart disease
Cost category Reduction in cost (%)
Hospital 0.16
Drugs 0.50
Physician care 1.00
Other direct 0.23
Mortality 1.00
Long-term disability 1.00
Short-term disability 1.00
Table 4. Summary of sensitivity analysis scenario assumptions
Scenario
Assumption Ideal (%) Optimistic (%) Pessimistic (%) Very pessimistic (%)
Success rate 47.0 17.0 10.0 5.0
Cholesterol reduction due to plant sterol consumption 10.8 9.7 8.5 5.0
CHD reduction due to 1% reduction in serum LDL-cholesterol 3.0 2.5 2.0 1.0
CHD reduction due to plant sterol consumption 32.4 24.3 17.0 5.0
Healthcare savings from plant sterol use in Canada
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The rising costs of health care exist as a growing concern
globally; especially in countries such as Canada where
direct costs of treating disease are borne largely by the
public health care systems. It has also been found that
the cholesterol-lowering effects of plant sterols are
additive to other cholesterol lowering strategies such as
diet (21) and statin treatment (22). As such, phytosterol
enhanced foods can work in concert with lifestyle changes
and medication to lower the economic cost of CHD.
A possible direction for future research would be to
explore the cost effectiveness of reducing CHD through
plant sterols in food products compared to statins, which
currently enjoy a cost advantage over sterols.
When considering the cost savings presented in this
analysis it should be noted that the cost premiums
associated with plant sterol-enriched foods have not
been accounted for in this valuation. The costs of
phytosterol fortified foods will fall outside of the medical
system in Canada and thus represent a benefit to the
publicly funded health care system. An excessive price
premium would result in a lower economic benefit
of plant sterol-enriched foods. As the market for phytos-
terol fortified foods develops and more is known about
possible price premiums, this issue should be revisited
with a costbenefit or cost-effectiveness study.
CHD is a substantial component of the economic
burden of illness in Canada and high serum cholesterol
is a major risk factor in developing CHD. Functional
foods such as those which contain plant sterols have the
potential to ‘demedicalize’ and reduce significant portion
of the economic costs associated with CHD in Canada,
which in turn would allow health care funds to be
allocated more efficiently.
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